Navigation Links
Spectral announces third quarter 2008 results
Date:11/12/2008

TORONTO, Nov. 12 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc. (TSX: SDI) today announced its financial results for the third quarter ended September 30, 2008.

"In September, Spectral took a major first step in the implementation of its strategy to align its diagnostic with a therapeutic for the treatment of severe sepsis. We agreed, with Toray Industries Inc., to key terms for the exclusive development and commercial rights in the U.S. for Toraymyxin(TM), a therapeutic for the treatment of sepsis that removes endotoxin from the bloodstream and has been used safely and effectively in over 70,000 patients in Japan and Europe since 1994," said Dr. Paul Walker, President and CEO of Spectral. "Combined with our Endotoxin Activity Assay, EAA(TM), the only FDA cleared diagnostic for the detection of endotoxin, we believe that this treatment can fulfill a major unmet need for the approximately 100,000 patients with elevated endotoxin levels that develop severe sepsis or septic shock in the U.S. each year."

Dr. Walker added: "We are in the process of completing our due diligence and we plan to meet with the U.S. FDA early in the first quarter to determine an appropriate clinical development pathway. Following the FDA's clearance of our clinical pathway, we expect to finalize the exclusive license and material supply agreements with Toray in the first quarter of 2009."

Financial Review

For the three months ended September 30, 2008, Spectral reported sales of $701,000 compared to $739,000 for the corresponding period in 2007. For the nine months ended September 30, 2008, the Company reported sales of $2,150,000, compared to sales of $2,318,000 for the same period last year. Sales of the Company's EAA(TM) diagnostic increased significantly, but the improvement was offset by lower royalty revenues. Certain pre-established royalty plateaus were reached in 2007, resulting in a reduction of $466,000 in related revenues for the first nine months of 2008. In future years, this temporary decrease should be offset as revenues from a new license agreement, which was signed in late 2007, start to be realized.

Selling, general and administrative expenses for the three months ended September 30, 2008 were $729,000, compared to $799,000 for the corresponding period in 2007. These expenses for the nine months ended September 30, 2008 were $2,295,000, compared to $2,375,000 for the same prior year period due to the continued maintenance of a low cost operating structure.

For the three months ended September, 2008, the Company reported a loss of $332,000 or ($0.01) per share compared to a loss of $382,000 or ($0.02) per share for the corresponding period in 2007. For the nine months ended September, 2008, the loss was $1,199,000 or ($0.05) per share, compared with a loss of $968,000 or ($0.04) per share for the corresponding period in 2007. The higher loss is attributable solely to the reduction in royalties.

Cash and short term investments at September 30, 2008 totalled $4,204,000 compared with $4,927,000 at December 31, 2007. Management expects that the Company will maintain a cash and short term investment balance of approximately $4,000,000 for the rest of the year.

About Spectral Diagnostics

Spectral is a leader in the battle against sepsis. Spectral's lead product is its Endotoxin Activity Assay (EAA(TM)), the only FDA cleared assay for the measurement of endotoxin. With the growing awareness for the role of endotoxemia in sepsis and the increasing number of therapies being developed for this indication, Spectral is well-positioned to promote the adoption of the EAA(TM), which can be used to identify patients, enable therapeutics and monitor treatment. Spectral is listed on TSX under the symbol SDI.

Forward-looking statement

Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.

The TSX has not reviewed and does not accept responsibility for the

adequacy or accuracy of this statement.

Spectral Diagnostics Inc.

Balance Sheets - unaudited

As at September 30, 2008 and December 31, 2007

-------------------------------------------------------------------------

(in thousands of dollars)

2008 2007

$ $

Assets

Current assets

Cash and cash equivalents 173 638

Short-term investments 4,031 4,289

Accounts receivable 716 677

Inventories 193 249

Prepaid expenses 72 55

---------------------

5,185 5,908

Property, plant and equipment 439 379

Commercial instruments 130 164

Purchased technology and trademarks 1,176 1,529

---------------------

6,930 7,980

---------------------

---------------------

Liabilities

Current liabilities

Accounts payable and accrued liabilities 351 379

Deferred revenue 139 150

Convertible note payable 2,131 2,008

---------------------

2,621 2,537

---------------------

Shareholders' Equity

Common shares 2,524 2,524

Other equity 5,671 5,606

Deficit (3,886) (2,687)

---------------------

4,309 5,443

---------------------

6,930 7,980

---------------------

---------------------

Spectral Diagnostics Inc.

Statements of Operations, Comprehensive Loss and Deficit - unaudited

For the nine months ended September 30, 2008 and 2007

-------------------------------------------------------------------------

(in thousands of dollars, except share and per share data)

3 Months Ended 9 Months Ended

September 30 September 30

2008 2007 2008 2007

$ $ $ $

Sales 701 739 2,150 2,318

Cost of sales 171 168 560 547

------------------------------------------------

Gross margin 530 571 1,590 1,771

------------------------------------------------

Operating expenses

Selling, general and

administrative 729 799 2,295 2,375

Amortization 160 147 478 433

Foreign exchange (gain)

loss (28) 27 (26) 81

Stock-based compensation 22 - 65 31

Research and product

development, net of tax

credits 4 - 29 (125)

------------------------------------------------

887 973 2,841 2,795

------------------------------------------------

Loss before the following (357) (402) (1,251) (1,024)

Interest expense on

convertible notes payable (41) (41) (123) (124)

Net interest income 66 61 175 180

------------------------------------------------

Loss and comprehensive

loss for the period (332) (382) (1,199) (968)

Deficit - Beginning of

period (3,554) (1,607) (2,687) (1,021)

------------------------------------------------

Deficit - End of period (3,886) (1,989) (3,886) (1,989)

------------------------------------------------

------------------------------------------------

Basic and diluted loss

per common share (0.01) (0.02) (0.05) (0.04)

------------------------------------------------

------------------------------------------------

Weighted average number of

common shares

outstanding 24,118,424 24,118,424 24,118,424 24,116,966

------------------------------------------------

------------------------------------------------

Spectral Diagnostics Inc.

Statements of Cash Flows - unaudited

For the nine months ended September 30, 2008 and 2007

-------------------------------------------------------------------------

(in thousands of dollars)

3 Months Ended 9 Months Ended

September 30 September 30

2008 2007 2008 2007

$ $ $ $

Cash provided by (used in)

Operating activities

Loss and comprehensive

loss for the period (332) (382) (1,199) (968)

Items not affecting cash

Amortization 160 147 478 433

Amortization of commercial

instruments included in

cost of sales 6 6 18 35

Stock-based compensation

expense 22 - 65 31

Interest on convertible

notes payable 41 41 123 124

Changes in non-cash working

capital 139 93 (28) (404)

--------------------- ---------------------

36 (95) (543) (749)

--------------------- ---------------------

Financing activities

Bank indebtedness (195) 314 - 349

Issuance of common shares - - - 4

--------------------- ---------------------

(195) 314 - 353

--------------------- ---------------------

Investing activities

Purchase of property, plant

and equipment (32) (182) (147) (230)

Purchase of commercial

instruments - - (22) (119)

Purchase of technology

and trademarks - - - (44)

Decrease (increase) in

short-term investments 359 (54) 258 (156)

Decrease in deferred revenue (3) - (11) -

--------------------- ---------------------

324 (236) (78) (549)

--------------------- ---------------------

Decrease in cash and cash

equivalents during the

period 165 (17) (465) (945)

--------------------- ---------------------

Cash and cash equivalents -

Beginning of period 8 17 638 945

--------------------- ---------------------

Cash and cash equivalents -

End of period 173 - 173 -

--------------------- ---------------------

--------------------- ---------------------


'/>"/>
SOURCE Spectral Diagnostics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Spectral to bring anti-sepsis therapy to the U.S. market
2. Spectral announces exclusive distribution agreement in Russia for its EAA(TM) Sepsis Diagnostic Assay
3. Spectral announces continuing support for the combination of EAA(TM) and anti-endotoxin therapeutics
4. Spectral announces presentation of data on improving sepsis patient management with EAA(TM) and Toraymyxin(TM) combination
5. Spectral and Toray expand collaboration to include new geographic territories
6. Spectrals EAA(TM) to be used in Phase III study for a sepsis anti-endotoxin therapy
7. Spectral announces new findings on the effectiveness of EAA(TM)/Toraymyxin(TM) at the 28th International Symposium on Intensive Care and Emergency Medicine
8. Spectral announces 2007 financial results
9. Spectral appoints Anthony Bihl to Board of Directors
10. Spectral announces data on the clinical utility of EAA(TM) to be presented at 12th Annual Critical Care for Endotoxemia Conference in Japan
11. CRi Announces Nuance 2, the Next-Generation Multispectral Imaging System for Brightfield and Fluorescent-Based Microscopy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... DIEGO , Feb. 5, 2016 On ... region,s trusted information source for community, health and disaster ... Diego) will integrate to enhance care coordination and ... to the services they need and to better connect ... improve care.   San Diego ...
(Date:2/5/2016)... -- Australian-US drug discovery and development company, Novogen Limited (ASX:NRT; ... new Chairman, Mr John O,Connor , and new Deputy ... James Garner , has also been formally appointed to ... Mr Iain Ross , will resume his role on ... Garner , has also been formally appointed to the Board ...
(Date:2/4/2016)... 2016 - New FDA action date of ... FDA action date of July 22, 2016   ... 22, 2016   - Lifitegrast has ... indicated for the treatment of signs and symptoms of dry eye ... potential to be the only product approved in the U.S. in the past decade indicated ...
(Date:2/4/2016)... ... February 04, 2016 , ... Shimadzu Scientific Instruments will ... live demos and poster sessions, and present on the analysis of mycotoxins and ... March 6 to 10 at the Georgia World Congress Center in Atlanta, Georgia. ...
Breaking Biology Technology:
(Date:2/4/2016)... , Feb. 4, 2016 The ... apparently one of the most popular hubs of ... MetaHIT and other huge studies of human microbiota, ... past few years, the microbiome space has literally ... biomedical research. This report focuses on biomedical ...
(Date:2/2/2016)... 2016  BioMEMS devices deployed in hospitals ... medical screening and diagnostic applications, such as ... that facilitate and assure continuous monitoring without ... being bolstered through new opportunities offered by ... coupled with wireless connectivity and low power ...
(Date:2/2/2016)... 2016  Based on its recent analysis of ... US-based Intelligent Retinal Imaging Systems (IRIS) with the ... New Product Innovation. IRIS, a prominent cloud-based retinal ... , is poised to set the new ... market. The IRIS technology presents superior price-performance value ...
Breaking Biology News(10 mins):